Memphasys Limited (FRA:IG7)

Germany flag Germany · Delayed Price · Currency is EUR
0.0015
+0.0005 (50.00%)
At close: Dec 4, 2025
-50.00%
Market Cap 5.57M
Revenue (ttm) 294.15K
Net Income (ttm) -2.81M
Shares Out n/a
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 2,629
Open 0.0015
Previous Close 0.0010
Day's Range 0.0015 - 0.0015
52-Week Range 0.0010 - 0.0060
Beta n/a
RSI 49.82
Earnings Date Nov 27, 2025

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2006
Employees 24
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol IG7
Full Company Profile

Financial Performance

In 2025, Memphasys's revenue was 526,921, an increase of 237.77% compared to the previous year's 156,000. Losses were -5.04 million, -6.19% less than in 2024.

Financial numbers in AUD Financial Statements

News

There is no news available yet.